GSK Pharmaceuticals: Ledger

Stories naming GSK Pharmaceuticals. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Investor	Rounds	Invested
No investors recorded yet. Know one?

Company	Kind	Announced	Price	Sources
GSK Pharmaceuticals is not recorded as having acquired anything.

Name	Role	Sources
Ruth Tal-Singer	Vice President of Medical Innovation (former)	Brandon Capital portfolio, Brandon BioCatalyst portfolio

Unnamed stage ≤$32m

ENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Fund Raise

ENA Respiratory secured up to AU$32 million, co-led by Brandon Capital Partners and Minderoo Foundation with Uniseed, to advance its INNA-051 nasal spray, and appointed Ruth Tal-Singer to its board.

Brandon BioCatalyst portfolio Tue 15 Jun 2021 ENA Respiratory CSIRO GSK Pharmaceuticals International COVID-19 Data Research Alliance Medical Research Commercialisation Fund (MRCF)The University of Sydney University of Melbourne University of Queensland UNSW Sydney US COPD Foundation Brandon Capital Partners Minderoo Foundation Uniseed Dr Andrew Forrest Dr Chris Smith Dr Christophe Demaison Nicola Forrest Ruth Tal-Singer

Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·SmartCompany·SmartCompany

GSK Pharmaceuticals

Funding history

Investors

What GSK Pharmaceuticals bought

People

Coverage

ENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Fund Raise